Zela

Quick links to important sections

Zela

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zela

Understanding Zela

Zela is a pharmacological treatment categorized as a selective serotonin reuptake inhibitor (SSRI). It is primarily utilized in the management of various mental health conditions, most notably major depressive disorder and several types of anxiety disorders. By influencing the chemical messengers within the brain, Zela aims to help stabilize mood and improve emotional well-being.

Mechanism of Action

The active component in Zela works by increasing the availability of serotonin, a neurotransmitter in the central nervous system. Serotonin plays a critical role in regulating mood, sleep, and appetite. Under normal physiological conditions, serotonin is released by neurons and then reabsorbed. Zela inhibits this reabsorption process, allowing more serotonin to remain in the synaptic gap between neurons, which facilitates improved communication between nerve cells and helps alleviate symptoms of depression and anxiety.

Clinical Applications

Zela is indicated for the treatment of several specific psychological conditions:

  • Major Depressive Disorder: Helping to relieve persistent feelings of sadness and loss of interest.
  • Panic Disorder: Assisting in the reduction of the frequency and intensity of panic attacks.
  • Social Anxiety Disorder: Managing the intense fear of social situations and interactions.
  • Obsessive-Compulsive Disorder (OCD): Addressing repetitive thoughts and behaviors.
  • Post-Traumatic Stress Disorder (PTSD): Supporting recovery following exposure to traumatic events.

Therapeutic Goals

The primary objective of treatment with Zela is the stabilization of emotional states. Unlike some medications that provide immediate relief, SSRIs like Zela typically require a period of consistent use before the full therapeutic effects are observed. The gradual adjustment of neurotransmitter levels is intended to provide a sustained improvement in daily functioning and overall quality of life.

Regulatory References

  1. World Health Organization

What side effects are possible with Zela?

Possible Side Effects and Safety Information

Zela (Albendazole) has an official safety profile categorized by system-organ class and frequency, as documented in regulatory labeling by health authorities like the FDA and EMA.

Commonly Documented Adverse Reactions

The most frequently reported side effects, typically affecting the Nervous System and Gastrointestinal Disorders classes, include headache, abdominal pain, nausea, and vomiting. Additionally, transient, usually reversible, elevations of hepatic enzymes (liver transaminases) are classified as a common occurrence during therapy.

Serious Adverse Reactions and Constraints

Regulatory documents emphasize the risk of serious but rare reactions, primarily concerning the Hepatobiliary Disorders and Blood and Lymphatic System Disorders. These include potential hepatotoxicity (liver injury) and bone marrow suppression, which may manifest as leukopenia or aplastic anemia. The official label mandates periodic monitoring of liver function tests and blood cell counts during treatment to observe these risks.

Population-Specific Safety Notes

Explicit safety constraints are documented for specific populations. The medicine is contraindicated in pregnancy and requires strict precautions for women of childbearing potential due to the documented risk of embryotoxicity. Caution is also required for individuals with pre-existing hepatic impairment, as they may be at an increased risk for more serious hepatic and hematological adverse effects. For systemic indications, some side effects are noted as being more frequent at the initiation of treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Zela


Overdose Scope

Documented Overdose Presentations: Overdose symptoms primarily involve the Central Nervous System (CNS). Clinical manifestations range from somnolence and confusion to more severe CNS depression, including coma. Cardiorespiratory collapse leading to fatal outcomes has been reported, especially in severe cases.

Dose-related or Exposure-related Factors: The greatest risk of a severe or fatal outcome is associated with polydrug overdose, particularly the co-ingestion of Zela with other CNS depressants such as alcohol or opioids. However, intentional overdose with Z-drugs alone is also a documented risk.

When Immediate Medical Help is Required: Urgent medical attention is required for any suspected overdose. Emergency action is critical if the person experiences severe CNS depression, has difficulty breathing, or cannot be aroused, as these symptoms can progress rapidly.


Overdose Management

Emergency-Response Statements: Management of Zela overdose is primarily supportive. This includes monitoring and maintaining the patient’s airway, breathing, and circulation. In certain clinical settings, the use of flumazenil (a GABA-A receptor antagonist) may be considered to reverse the sedative effects.

Population-Specific Overdose Notes: Overdose risk is associated with concurrent use of CNS depressants (including alcohol), a factor that necessitates immediate and professional medical intervention due to the potential for synergistic depressive effects on the respiratory system.


Connection to the Overall Overdose Profile: Official regulatory documents characterize the overdose profile as a spectrum of escalating CNS depression, from simple sedation to life-threatening coma. The critical factor governing severity and the need for emergency care is often the concomitant ingestion of other depressant substances, a circumstance specifically noted in regulatory safety communications.

Therapeutic Uses of Zela

What Zela Treats: Main Uses and Benefits

Zela (duloxetine) is a prescription medicine applied across domains where additional symptomatic support is needed. It is commonly used for managing symptom clusters related to both mood and physical discomfort.

The medicine is considered relevant in conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), Chronic Musculoskeletal Pain (such as chronic low back pain), and Fibromyalgia (FM). The medication may help with managing symptoms that interfere with daily comfort and emotional tension across these varied clinical scenarios.

Zela may assist with easing the overall symptom burden associated with these conditions. This medication supports patients during episodes of heightened discomfort and supports general well-being during symptomatic phases.


Quick Fact: Applied to support symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zela (Albendazole)

Category Official Regulatory Status
Contraindicated Populations Known hypersensitivity to the benzimidazole class of compounds; Pregnancy
Restricted Use Patients with liver disease; Patients with bone marrow suppression
Age Group Eligibility Established for Adults and Pediatric patients (typically ge 2 years); Pharmacokinetics not studied in renal impairment

Zela (Albendazole) is contraindicated for patients with a known hypersensitivity to the benzimidazole drug class. Use is also prohibited during pregnancy due to the risk of fetal harm; a negative pregnancy test is required prior to starting therapy for females of reproductive potential, who must also use effective contraception during and for a period after treatment [1.8, 3.3].

Conditional use is required for patients with pre-existing liver disease or bone marrow suppression [1.4, 3.3]. These populations are eligible only if liver enzymes and blood counts are closely monitored before and during the treatment course [1.8]. Pediatric and adult populations are eligible for use, but use is often not recommended in children under two years of age [2.4]. The official pharmacokinetics of Zela in patients with impaired renal function have not been studied [3.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Zela (Duloxetine) based on metabolic pathway interference and additive pharmacodynamic effects.

Contraindicated Combinations

The co-administration of Zela is formally contraindicated with certain drug classes due to significant risk:

  • Nonselective, Irreversible Monoamine Oxidase Inhibitors (MAOIs): Combining these agents is prohibited due to the risk of severe reactions, requiring a specific washout period of 5 to 14 days when switching treatments.
  • Potent CYP1A2 Inhibitors: Substances such as fluvoxamine are prohibited because they can significantly increase Zela's plasma concentrations (exposure), leading to a higher risk of adverse effects.

Other Clinically Significant Interactions

Interaction Type Interacting Agents (Examples) Official Effect
Serotonergic Load Triptans, Tramadol, St. John's Wort Increased risk of Serotonin Syndrome.
Metabolic Inhibition Potent CYP2D6 Inhibitors (e.g., Paroxetine) Increases Zela's exposure.
CNS Additive Effects Sedative Medicines, Alcohol Heightened CNS effects.
Bleeding Risk NSAIDs, Warfarin, Aspirin Increased risk of bleeding events.

Population-Specific Constraints

The product is contraindicated for use in patients with severe hepatic impairment or severe renal impairment (Creatinine Clearance < 30 mL/min), as these conditions are officially documented to substantially increase drug exposure.

Mechanism of Action

Disrupting the Parasite's Structural Core

Zela's mechanism is defined by its high-affinity binding to the parasite's beta-tubulin protein. As an inhibitor of polymerization, the drug prevents these subunits from assembling into functional microtubules, causing the systematic loss of the parasite's cellular integrity. Microtubules are necessary for the cell's structural support, motility, and intracellular transport. This direct structural sabotage defines this primary mechanistic domain.


Crippling Parasitic Energy Metabolism

This domain focuses on the complementary metabolic action of the drug. Zela interferes with the parasite’s specific glucose transport system, blocking the uptake of necessary nutrients. This leads to the depletion of the parasite’s glycogen stores and interrupts the energy supply necessary for ATP generation and mitosis. This resulting metabolic exhaustion results in a progressive state of metabolic exhaustion and functional impairment across the adult, larval, and ovicidal (egg-killing) stages.

Dosage and Administration Information

How to Use Zela

Zela, containing the active ingredient Albendazole, is administered exclusively through the oral route. Its usage patterns are strictly defined by the specific infection being addressed, dictating both the required dose and the total duration of the course. The drug is available in several forms, including oral tablets, chewable tablets, and oral suspension.


Administration and Timing

The fundamental condition for using Zela is its requirement to be taken with a fatty meal. This practice is essential as it significantly enhances the medicine's systemic absorption (bioavailability), particularly when treating systemic infections. The tablets may be crushed or chewed and swallowed with a drink of water, providing flexibility for patients who have difficulty swallowing whole tablets.


Dosing and Treatment Cycles

Dosing frequency varies from a single oral dose of 400 mg for common intestinal parasitic infections to a more complex twice-daily regimen for systemic diseases. For conditions such as Hydatid Disease and Neurocysticercosis, the standard adult regimen is 400 mg twice daily for patients weighing 60 kg or more, with the total dose not exceeding 800 mg per day.

Treatment for systemic infections is structured into cycles. For Hydatid Disease, therapy consists of a 28 -day cycle followed by a 14 -day drug-free interval, which is repeated for a total of three cycles. No adjustment is typically necessary for older adults or those with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zela (Albendazole)

This overview summarizes the available research and clinical studies for Zela, focusing on what scientists have investigated and what remains uncertain, based on official regulatory and scientific documents. It does not offer medical advice, dosing instructions, or safety information.


Evidence for Management of Soil-Transmitted Helminths (STH)

Research exploring Zela in contexts of common intestinal infections, such as those caused by roundworm (Ascaris lumbricoides) and hookworm, is extensive. This area has been evaluated through a large number of Randomized Controlled Trials (RCTs), which represent a rigorous type of clinical evidence, alongside many systematic reviews and public health studies.

Researchers primarily examined parasitological outcomes, focusing on objective measurements like the Cure Rate, which tracks the measurement of parasite clearance from the stool, and the Egg Reduction Rate, which tracks the measured change in the number of eggs observed. Studies monitored these changes in school-aged children and other populations in areas where these infections are common.

Findings described measurements of parasite clearance in studies involving roundworm and hookworm infections. Research provides context that these large-scale programs help contextualize how treatment was studied for populations with varying infection burdens. For another common parasite, the Whipworm (Trichuris trichiura), findings were mixed, with some studies reporting lower rates of parasitic clearance when Zela was used alone.


Evidence for Management of Neurocysticercosis

Zela was studied for research exploring the context of parasitic cysts in the brain. The research here includes Controlled Trials that studied specific outcomes related to this condition.

Studies explored outcomes related to physical changes observed in the brain. Researchers monitored outcomes using imaging technologies like MRI or CT scans to measure the number of cysts and observe whether they resolved or calcified during the study period. Additionally, research monitored functional outcomes by tracking the frequency of associated seizures in the observed populations over defined time intervals. Findings describe group patterns related to cyst status following treatment.

What remains uncertain is the full scope of long-term functional and cognitive outcomes beyond cyst clearance or initial seizure control. Furthermore, because patients often require other medications (such as anti-inflammatory drugs) to manage inflammation associated with parasite death, the evidence provides limited insight into Zela's specific contribution when used without these co-administered drugs.

Key Studies & References

  1. Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda—A Prospective Cohort Study
  2. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials
  3. Application for inclusion of albendazole, mebendazole and praziquantel on the WHO Model List of Essential Medicines (EML) - World Health Organization (WHO)

Frequently Asked Questions (FAQ)

Common questions about Zela (FAQ)

Q: Can I take Zela long-term?

A: For specific systemic infections, Zela is prescribed in repeated 28-day treatment cycles, which are followed by drug-free intervals. Due to potential risks, the official label requires monitoring of liver and blood cell counts throughout the course of therapy.


Q: Can Zela cause unusual mood changes or sleep problems?

A: Official regulatory documents list adverse effects related to the nervous system, such as headache and dizziness. In patients treated for Neurocysticercosis, neurologic symptoms have been reported. If you experience concerning symptoms, it is recommended to speak with a healthcare professional.


Q: Does Zela interact with common pain relievers like ibuprofen?

A: Official product information indicates that co-administration with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as ibuprofen, may be associated with an increased risk of bleeding events.


Q: What foods or supplements should I avoid when using Zela?

A: Official guidance states that Zela should be taken with food to help increase its absorption. Additionally, the regulatory information notes that consuming grapefruit juice may increase the amount of the drug in the blood.


Q: Is Zela safe for older adults (seniors)?

A: The official product information indicates that a dose adjustment is typically not necessary for older adults based on age alone. However, general precautions related to pre-existing conditions, particularly involving the liver and kidneys, apply to all patients.


Q: What is the research evidence supporting the use of Zela?

A: Official regulatory documents include summaries of extensive clinical studies, such as Randomized Controlled Trials (RCTs). This research established the medicine's efficacy in treating its specified parasitic infections.


Q: What are the signs of an allergic reaction to Zela?

A: Zela is contraindicated (prohibited) if a patient has a known hypersensitivity to the benzimidazole class of compounds. Signs of a severe allergic reaction require immediate medical attention.


Q: Is it normal to feel slightly dizzy after starting Zela?

A: Yes, regulatory documents list dizziness (vertigo) as a common adverse reaction reported in clinical trials. As dizziness is reported, patients should consider how this may affect their ability to drive or operate machinery.


Q: What kind of monitoring (e.g., blood tests) is sometimes needed with Zela?

A: The official label mandates periodic monitoring of liver enzymes and blood cell counts (CBC) during therapy. This monitoring is required to check for potential adverse effects such as changes in liver enzymes and blood cell counts.


Q: Can Zela cause problems if I stop taking it suddenly?

A: The official documentation does not list withdrawal symptoms specific to Zela. However, specific protocols are required when switching from certain other medications to Zela.


Q: Are there any significant warnings or precautions for Zela users?

A: Yes. Regulatory documents list warnings regarding the potential risks of Bone Marrow Suppression and Hepatic Effects. Due to the potential risk of fetal harm, Zela is also contraindicated during pregnancy.


Q: Does Zela affect fertility in men or women?

A: Regulatory documents recommend that females of reproductive potential use effective contraception during treatment and for a period afterward due to the risk of harm to an unborn baby. Effects on male fertility are not explicitly addressed in the official product information.


Q: How quickly does Zela start to show an effect?

A: Official pharmacokinetic studies indicate that the active form of the medicine (albendazole sulfoxide) typically reaches its highest concentration in the blood within approximately 2 to 5 hours after it is taken.


Q: Can Zela affect my driving or ability to operate machinery?

A: Common side effects include dizziness and headache, which may affect attention and motor skills. This risk may be heightened if the medicine is taken alongside alcohol or other sedating medicines.


Q: Is a generic version of Zela available?

A: Yes. The active ingredient, albendazole, has been approved by regulatory bodies and is available as a generic formulation.


Q: Can Zela be crushed or split if it's a tablet?

A: The official instructions indicate that the tablets may be crushed or chewed and then swallowed with water. This method of administration is noted in the regulatory documentation.


Q: Does Zela interact with birth control pills?

A: Due to the severe risk of fetal harm, regulatory labels advise that females of reproductive potential must use effective contraception while taking Zela. Specific two-way pharmacokinetic interactions with oral contraceptives are not detailed in the product information.


Q: Are there any specific organs that Zela affects most?

A: Yes, official regulatory warnings highlight the potential for effects on the liver (hepatotoxicity) and the bone marrow (suppression). Monitoring these systems is mandated during treatment.


Q: How long does Zela stays in your system?

A: Official pharmacokinetic data indicates that the active substance in Zela (albendazole sulfoxide) has an elimination half-life of approximately 8 to 12 hours. This is the time it takes for half of the substance to be eliminated from the body.


Q: Do over-the-counter cold and flu medicines interact with Zela?

A: Interactions can occur with certain ingredients found in cold and flu medicines. Regulatory documents caution against combining Zela with agents that increase bleeding risk (like NSAIDs) or those that heighten Central Nervous System effects (like certain sedatives).


Q: What makes Zela different from a placebo in clinical trials?

A: Clinical trials summarized in regulatory documents demonstrated that Zela was more effective than a placebo (an inactive treatment). The studies confirmed its superiority in achieving defined outcomes, such as the elimination of parasites or reduction of eggs.


Q: Is Zela used in combination with other treatments?

A: Yes, for the treatment of specific conditions like Neurocysticercosis, the official label notes that Zela is often used alongside other necessary treatments, such as appropriate steroid and anticonvulsant medications.


Q: Can Zela cause changes to my skin?

A: One reported adverse reaction noted in the clinical trial data is reversible alopecia (hair loss). Any severe skin reaction, while rare, falls under general drug hypersensitivity warnings.


Q: Is the effectiveness of Zela reduced by alcohol consumption?

A: Regulatory documents explicitly warn that alcohol consumption can heighten the Central Nervous System effects of Zela. Official information does not specify whether alcohol reduces the medicine's anti-parasitic effectiveness.

How should Zela be stored and disposed of?

How to Store and Dispose of Zela (Albendazole)

The official labeling for Zela (Albendazole) defines precise conditions required for storage, handling, and disposal.

Storage Requirements

Scope Component Official Regulatory Requirement
Labeled storage temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Light/moisture protection Protect from light and moisture; do not store in areas like the bathroom.
Handling requirements Do not allow the medicine to freeze.
Packaging-related storage Keep the medicine in the original container with the cap tightly closed.

Disposal Instructions

To dispose of unused or expired Zela, the regulatory guidance specifies using an authorized drug take-back program. If a take-back option is unavailable, the medicine must be prepared for household trash by mixing it with an unappealing substance (e.g., used coffee grounds or kitty litter) and sealing it in a plastic bag before discarding. The medicine must be kept out of the sight and reach of children, and not flushed down the toilet or poured into the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zela found in:

A-Z Index: